BLUE SKY BREAKOUT

[QuicKtip]

$BCTX BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with FDA for Bria-PROS+™ in prostate cancer https://www.globenewswire.com/news-release/2024/09/10/2943571/0/en/BriaCell-Announces-Positive-Pre-IND-Meeting-with-FDA-for-Bria-PROS-for-Prostate-Cancer.html

[QuicKtip]

$CBDW great time presenting at the 150th NIBA show last week.

great time presenting at the 150th NIBA show last week. pic.twitter.com/rmBRVSoHLk

— CBDW.ai | A Brand by 1606 Corp (@CBDWInc) September 10, 2024

[QuicKtip]

$VINO Gaucho Holdings Announces Collaboration with Renowned Argentine Artist Aldo Sessa
https://finance.yahoo.com/news/gaucho-holdings-announces-collaboration-renowned-143000334.html

[QuicKtip]

$UNCY Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis https://finance.yahoo.com/news/unicycive-therapeutics-announces-submission-drug-110300693.html

[QuicKtip]

$LPTH LightPath Technologies Achieves Key Qualification Milestone With Lockheed Martin for US Army Missile Program https://finance.yahoo.com/news/lightpath-technologies-achieves-key-qualification-123000761.html

[QuicKtip]

$DYAI Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress https://finance.yahoo.com/news/dyadic-announces-second-quarter-2024-200500776.html

[QuicKtip]

Why Now is the Time to Invest in AI Technology $CBDW https://cbdw.ai/why-now-is-the-time-to-invest-in-ai-technology/

[QuicKtip]

$CBDW 1606 Corporation Forges Ahead with Strategic Stake in Adnexus https://allcapresearch.com/penny-stocks/f/1606-corporation-forges-ahead-with-strategic-stake-in-adnexus

[QuicKtip]

$CBDW 1606 Corp: Pioneering AI Chatbots in CBD and Investor Relations https://allcapresearch.com/f/cbdw-pioneering-ai-chatbots-in-cbd-and-investor-relations

[QuicKtip]

$AIMD Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety https://finance.yahoo.com/news/ainos-unveils-ai-nose-breakthrough-131500402.html

[QuicKtip]

$DYAI Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership https://finance.yahoo.com/news/dyadic-international-inc-proliant-health-123000731.html @chazzsheen3

[QuicKtip]

$VINO Gaucho Holdings' Algodon Fine Wines Expands U.S. Distribution Network With Pasanella & Son Vintners https://finance.yahoo.com/news/gaucho-holdings-algodon-fine-wines-170000340.html

[QuicKtip]

$CBDW 1606 Corp’s Strategic Plans for Q3 2024: Spotlight on the NIBA Show in Florida
https://cbdw.ai/1606-corps-strategic-plans-for-q3-2024-spotlight-on-the-niba-show-in-florida/

[QuicKtip]

#BREAKINGNEWS: $AMPG AmpliTech Group’s AGTGSS Division To Participate At Mobile World Congress Shows in Las Vegas And Barcelona To Market Its Comprehensive Private 5G End-to-End Solution for Businesses and Homes https://finance.yahoo.com/news/amplitech-group-agtgss-division-participate-130000431.html @chazzsheen3

[QuicKtip]

$CBDW CBDW AI Chatbot: Leading the Way in Investor Relations https://allcapresearch.com/f/1606-corp-ceo-with-key-highlights-from-recent-redchip-interview

[Singhania]

$VVPR Looks Great - Here is Why
$VVPR looks great on the chart. Higher highs and higher lows. Moreover, the stock is now trading above all the key Moving averages.

Next stop could be $3.50+++

[nickeli54]

$AAGC Conference call highlights from last night’s call!

🔥🔥 $AAGC 🔥🔥$AAGC 🔥Hollywood Star Cuts! High level points from tonight’s conference call: (Playback posted tomorrow)
💥Total of 13 new franchise locations opening all completed by March 2025 (30+ locations)
💥 No debt will be taken all cash on hand
💥 Qtr ends next week… pic.twitter.com/mvEkIZaRNM

— Nickeli (@nickeli54) August 28, 2024

[QuicKtip]

$AMPG News: AmpliTech Group’s AGMDC Division Moves to Allen Tech Hub in Watters Creek District In Allen Texas

https://finance.yahoo.com/news/amplitech-group-agmdc-division-moves-133000969.html

[QuicKtip]

$VINO Gaucho Holdings Announces Collaboration with Renowned Argentine Artist Aldo Sessa
https://finance.yahoo.com/news/gaucho-holdings-announces-collaboration-renowned-143000334.html

[QuicKtip]

$AIMD Company invites shareholders and all interested parties to learn our journey for ultimately becoming AI's nose capable of digitizing smell. https://finance.yahoo.com/news/ainos-participate-h-c-wainwright-123000697.html

[QuicKtip]

$DYAI Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress https://finance.yahoo.com/news/dyadic-announces-second-quarter-2024-200500776.html

[QuicKtip]

$CBDW 1606 Corp CEO with Key Highlights from Recent Redchip Interview https://allcapresearch.com/penny-stocks/f/1606-corp-ceo-with-key-highlights-from-recent-redchip-interview

[ProfitScout]

$GNPX: Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Chief Medical Officer Provides Overview of Recent Positive Clinical Patient Outcomes

Video Highlights Recent Oncology Clinical Development Program Updates

AUSTIN, Texas, Aug. 15, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today released a new video featuring the Company's Chief Medical Officer, Mark Berger, MD, discussing positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the Company's oncology clinical development program.

The Acclaim-1 clinical trial is evaluating the combination of the Company's lead drug candidate, Reqorsa® Gene Therapy, and AstraZeneca's Tagrisso® to treat patients with late-stage NSCLC who have activating EGFR mutations and disease progression after treatment with Tagrisso.

The Acclaim-3 clinical trial is evaluating the combination of REQORSA and Genentech's Tecentriq® as a maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.

Dr. Berger remarked on the two positive patient outcomes in Acclaim-1:
"Both of these patients' outcomes are fairly remarkable in terms of their prolonged Progression Free Survival (PFS) among patients in the study who were progressing on their previous treatment when they came into the study. It's very compelling, particularly, that one of those patients has maintained this benefit for more than two years. And over time, the patients' side effects with the combination of REQORSA and Tagrisso have diminished rather than increased over time."

Dr. Berger's commentary on the positive patient outcome in Acclaim-3:
"In the Acclaim-3 study, the first patient treated in the Phase 1 dose escalation portion of the trial has had a positive response since enrollment and starting maintenance therapy. The patient has a partial remission (PR) from the start of maintenance therapy until after the second course, which is when the first CT scan is done. This is the first dose group in this study, and there is a second higher dose group to come. The patient's response is remarkable, and it is very unusual to have a PR during maintenance therapy. We believe these results bode very well for the study."

On recent updates to the Company's oncology clinical development program, Dr. Berger stated:
"To build on these positive patient results, we are making changes to our clinical development program both in the Acclaim-1 and Acclaim-2 studies. In the Acclaim-1 study, we are removing one of the cohorts in Phase 2a, which will allow us to advance more quickly. The Acclaim-2 study is being closed to further enrollment. It has been slow to enroll patients, mainly because there are hundreds of other very similar studies that evaluate new treatments after patients have progressed on Keytruda®. We certainly intend to continue to treat patients in this study until they have disease progression. We also believe closing to further enrollment is the right thing to do so that we can focus our limited resources on the fastest way to being able to enroll patients and get clinical data.

We're very excited by these positive patient responses, and we look forward to advancing REQORSA through the clinic. We believe that streamlining our efforts to do so is the best way to use our resources and to move our program forward."

To watch the video, please visit Genprex's website at https://www.genprex.com/videos/.

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the initial patient responses to REQORSA treatments and the potential and promise of these responses, which are demonstrating early evidence of efficacy with a favorable safety profile; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
[e-mail]

GNPX Media Contact
Kalyn Dabbs
[e-mail]

https://c212.net/c/img/favicon.png?sn=DA84592&sd=2024-08-15 View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-releases-new-video-featuring-chief-medical-officer-discussing-positive-patient-outcomes-in-two-lung-cancer-clinical-trials-302223226.html

SOURCE Genprex, Inc.

[QuicKtip]

$VINO announced the appointment of David Reinecke to the Company's Board of Directors effective August 16, 2024. https://finance.yahoo.com/news/strategic-appointment-underscores-commitment-leveraging-160000371.html

[QuicKtip]

$AIMD AI Nose now has a 79% accuracy in identifying 761 samples across 22 VOCs in Japanese semiconductor manufacturing factories https://finance.yahoo.com/news/ainos-unveils-ai-nose-breakthrough-131500402.html

[QuicKtip]

$AMPG announced the signing of a Memorandum of Understanding (MOU) with a USA based IP Data Networking company to deploy a Private 5G Network in the state of California. https://finance.yahoo.com/news/amplitech-group-agtgss-division-signs-123000765.html

[QuicKtip]

$CBDW Ambitious Growth Targets https://allcapresearch.com/f/1606-corp-ceo-with-key-highlights-from-recent-redchip-interview

[QuicKtip]

$DYAI: Product Revenues Next Year https://finance.yahoo.com/news/dyai-product-revenues-next-102100332.html

[ProfitScout]

$YGMZ Investor Overview: https://ir.szygmz.com/investor-overview/

About MingZhu Logistics Holdings Limited (Nasdaq: YGMZ)

Established in 2002 and headquartered in Shenzhen, China, MingZhu Logistics Holdings Limited is a 4A-rated professional trucking service provider. Based on the Company's regional logistics terminals in Guangdong Province, MingZhu Logistics Holdings offers tailored solutions to our clients to deliver their goods through our network density and broad geographic coverage across the country by a combination of self-owned fleets tractors and trailers and subcontractors' fleets. For more information, please visit https://ir.szygmz.com/.

[QuicKtip]

$CBDW New blog is out!

Take a look at our blog from Monday.https://t.co/O0wAzMFX3O

— CBDW.ai | A Brand by 1606 Corp (@CBDWInc) August 21, 2024

[QuicKtip]

$AIMD Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024 https://finance.yahoo.com/news/ainos-participate-fireside-chat-water-120000950.html

[QuicKtip]

$VINO Gaucho Group Holdings, Inc. Expands Argentine Offerings With Algodon Extra Virgin Olive Oil https://finance.yahoo.com/news/gaucho-group-holdings-inc-expands-133000388.html

[QuicKtip]

$AMPG announced the company will host an investor conference call on Wednesday, August 28th, 2024 at 5:00 PM ET. https://finance.yahoo.com/news/amplitech-group-hold-q2-2024-133000215.html

[ProfitScout]

$YGMZ: Contract Awarded to MingZhu's Feipeng Subsidiary from Sinotrans Logistics for Vehicle Transport

SHENZHEN, China, July 10, 2024 /PRNewswire/ -- MingZhu Logistics Holdings Limited ("MingZhu" or the "Company") (Nasdaq: YGMZ), an elite provider of logistics and transportation services to businesses, today announced Sinotrans Logistics Northwest Co., Ltd. ("Sinotrans Logistics" https://logistics.sinotrans.com/) awarded a major 1-year vehicle transport contract to MingZhu's subsidiary Shanghai Feipeng Supply Chain Management Co., Ltd. ("Feipeng").

Under the contract, Feipeng will provide automobile transportation service to Sinotrans Logistics through June 2025. Feipeng will be transporting new energy commercial vehicles for Sinotrans Logistics from its customer Zhejiang Geely Holding Group Co., Ltd.'s nationwide factory to agreed-upon destinations across China. Sinotrans Logistics contracted Feipeng to initially provide 100 trucks on the route during the contract period.

Mr. Jinlong Yang, Chairman and Chief Executive Officer of MingZhu Logistics Holdings Limited, commented, "This showcase win demonstrates our capacity to flawlessly support high-profile customers and positively impacts our business financially. This capability is fueling significant momentum and growth for our company. Moreover, this achievement is a substantial win for our investors, reflecting our dedication to unlocking greater value."

Feipeng Logistics, a subsidiary of MingZhu, was founded in 2014. It provides integrated solutions to the logistics supply chain that reduce costs and increase efficiency. Feipeng Logistics is based in China's Xinjiang Autonomous Region, a strategically important location for manufacturing and commerce.

Sinotrans Logistics Co., Ltd. ("Sinotrans Logistics" https://logistics.sinotrans.com/) is the flagship of the contract logistics sector of Sinotrans Co., Ltd., a unified operating platform for the development of modern logistics business by China Merchants Group Co., Ltd., and is also one of the largest contract logistics companies in China. It is listed on both the Hong Kong and Shanghai Stock Exchanges. Sinotrans Logistics operates five business platforms: international supply chain, automobile transport, smart warehousing, multimodal transport and supply chain finance, focusing on the "5+1" industry fields of pan-consumer goods, technology electronics, medical health, automobile and industrial manufacturing, new retail and special logistics. It has carried out in-depth and extensive cooperation with many Fortune 500 customers and government agencies such as Procter & Gamble, Mobil, GE, Philips, Mars, Nestlé, Metro, Kimberly-Clark, BLACKWOODS, Kmart, etc., and has won widespread praise from customers.

About MingZhu Logistics Holdings Limited (Nasdaq: YGMZ)

Established in 2002 and headquartered in Shenzhen, China, MingZhu Logistics Holdings Limited is a 4A-rated professional trucking service provider. Based on the Company's regional logistics terminals in Guangdong Province, MingZhu Logistics Holdings offers tailored solutions to our clients to deliver their goods through our network density and broad geographic coverage across the country by a combination of self-owned fleets tractors and trailers and subcontractors' fleets. For more information, please visit https://ir.szygmz.com/.

Forward-Looking Statements

The statements in this press release regarding the Company's future expectations, plans and prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding plans, goals, objectives, strategies, future events, expected performance, assumptions and any other statements of fact that have not occurred. Any statements that contain the words "may", "will", "want", "should", "believe", "expect", "anticipate", "estimate", "calculate" or similar statements that are not factual in nature are to be considered forward-looking statements. Actual results may differ materially from historical results or from those expressed in these forward-looking statements as a result of a variety of factors. These factors include, but are not limited to, the Company's strategic objectives, the Company's future plans, market demand and user acceptance of the Company's products or services, technological advances, economic trends, the growth of the trucking services market in China, the Company's reputation and brand, the impact of industry competition and bidding, relevant policies and regulations, fluctuations in China's macroeconomic conditions, and the risks and assumptions disclosed in the Company's reports provided to the CSRC (China Security Regulatory Commission). The potential acquisition involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements including but not limited to statements about the potential benefits of the potential acquisition; the anticipated timing of closing of the potential acquisition (including failure to obtain necessary regulatory approvals) and the possibility that the potential acquisition does not close; risks related to the ability to realize the anticipated benefits of the potential acquisition, including the possibility that the expected benefits from the proposed transaction will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the potential acquisition making it more difficult to maintain business and operational relationships; negative effects of announcing the potential acquisition or the consummation of the potential acquisition on the market price of our common stock or operating results; costs associated with the potential acquisition; unknown liabilities; and the risk of litigation and/or regulatory actions related to the potential acquisition. For these and other related reasons, we advise investors not to place any reliance on these forward-looking statements, and we urge investors to review the Company's relevant SEC filings for additional factors that may affect the Company's future results of operations. The Company undertakes no obligation to publicly revise these forward-looking statements subsequent to the filing of these documents as a result of changes in particular events or circumstances.

https://c212.net/c/img/favicon.png?sn=CN58141&sd=2024-07-10 View original content:https://www.prnewswire.com/news-releases/contract-awarded-to-mingzhus-feipeng-subsidiary-from-sinotrans-logistics-for-vehicle-transport-302192718.html

SOURCE MingZhu Logistics Holdings Limited

[QuicKtip]

$JETR Star Jets aims to expand its clientele base, offering exclusive and tailored travel solutions that meet the unique demands of affluent individuals and corporate clients. https://finance.yahoo.com/news/star-jets-international-otc-jetr-125000390.html

[QuicKtip]

$AMPG announced the company will host an investor conference call on Wednesday, August 28th, 2024 at 5:00 PM ET. https://finance.yahoo.com/news/amplitech-group-hold-q2-2024-133000215.html

[QuicKtip]

$AIMD AI Nose can be integrated into robotics systems in smart factories, serving as the digital nose of AI technology https://finance.yahoo.com/news/ainos-unveils-ai-nose-breakthrough-131500402.html

[QuicKtip]

$CBDW AI Chatbot: Leading the Way in Investor Relations https://allcapresearch.com/f/1606-corp-ceo-with-key-highlights-from-recent-redchip-interview

[QuicKtip]

OTCQB: $DFCO partnered with ATI NY to boost sales of their heat pumps across key U.S. regions, including major markets like NYC, Chicago, and Miami. This agreement sets the stage for significant sales growth. Learn more: https://accesswire.com/904255/dalrada-financial-corporation-finalizes-exclusive-master-distribution-agreement-with-applied-technologies-of-new-york…

$DFCO #HeatPumps #CleanEnergy

[ProfitScout]

$NAHD News: New Asia Holdings Inc (NAHD) Announces Closing of Asset Purchase Agreement with Taylor Consulting (TAYO)

New Asia Holdings/Olenox Corp. Acquires Pipeline assets in Texas for $1,600,000 in common stock

Electra, Texas , Aug. 13, 2024 (GLOBE NEWSWIRE) -- New Asia Holdings Inc./Olenox Corp. (“NAHD” or the Company) (OTCQB: NAHD), announces it has purchased a 162 miles of Texas pipeline from Taylor Consulting (OTC:TAYO). The purchase, valued at $1,600,000, was paid by 10,000,000 shares of common stock of NAHD. The Company believes the acquired assets will be a key property moving forward. The acquired asset is 162 miles of pipeline designated as a public utility with associated feeder wells and a large consumer customer attached.

“We are excited about this acquisition as it moves our company into the midstream market and provides a solid cash-flowing asset,” said Olenox CEO Michael McLaren. “We will begin to re-establish take-off agreements and upgrade the pipeline over the next few months”.

The company will introduce its in-house monitoring technologies to increase field efficiencies, reduce costs and better protect the environment during the operation of the pipeline.

About Olenox Corp.
Olenox Corp.is a diversified energy company based in the state of Texas that currently operates three vertically integrated business units – Oil and Gas, Energy Services and Energy Technologies.

Oil and Gas: focuses on acquiring and optimizing underdeveloped oil and gas assets in Texas, Kansas and Oklahoma. It employs both internally developed and third party-licensed technologies to increase production, optimize performance and reduce costs. Olenox currently operates several oil and gas properties in Texas and Kansas.
Energy Services: This business unit supports Olenox’s overall exploration and production efforts with “well services” and “end of life reclamation.” Olenox Energy Services owns and operates a combination of customized service-wireline rigs and HydroVac units. This specialized equipment allows for faster “rig in” and “rig out” times. Overall, Olenox Energy Services’ equipment and experience combination seeks to reduce the amount of time and fuel burned to complete an abandonment or workover thus reducing costs.
Energy Technologies: This business provides both R&D and existing technology to enable increased production in the field. Olenox flagship intellectual property is its downhole enhanced recovery plasma pulse tooling and ultrasonic cleaning tools.
Each of Olenox’s three vertically integrated business units operate in tandem to help Olenox capture unique opportunities that often go untapped by the Company's competitors.

Facebook: https://www.facebook.com/OlenoxCorp
Instagram: https://www.instagram.com/olenoxcorp/
Twitter: https://x.com/OlenoxCorp
YouTube: https://www.youtube.com/@OlenoxCorp
Linkedin: https://www.linkedin.com/company/olenoxcorp/

Safe Harbor Statement: Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the Company's SEC filings. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.

https://www.globenewswire.com/newsroom/ti?nf=OTIwMzg2OSM2NDIxNDQzIzIyOTMzNTI=
https://ml.globenewswire.com/media/YmU3NzBkZjgtZjdjNC00MDg4LWE5ZGItYWQ1ZGYxMDZjZjZiLTEzMDQ5MDI=/tiny/New-Asia-Holdings-Inc-.png
For more information, please contact:
Olenox Corp.
205S Bailey Street, Electra, Texas 76360
Email: [e-mail]
Phone: [phone]

Source: New Asia Holdings Inc

[QuicKtip]

$AIMD announced that it has obtained exclusive licenses for a total of 10 invention patents and patent applications from Taiwan Carbon Nano Technology ("TCNT"), the Company's affiliate and product co-developer. https://finance.yahoo.com/news/ainos-secures-exclusive-multi-regions-201500321.html

[QuicKtip]

$VINO This new collaboration will enable 3Js Imports to represent Algodon Fine Wines across the United States, expanding the brand's national presence. https://finance.yahoo.com/news/gaucho-holdings-algodon-fine-wines-131500393.html

[QuicKtip]

$AMPG AmpliTech Group’s AGTGSS Division Unveils Comprehensive Private 5G End-to-End Solution for Businesses and Homes https://finance.yahoo.com/news/amplitech-group-agtgss-division-unveils-133000392.html?_fsig=uTlSaRlVkaSV69JE0FrfvA--%7EA

[QuicKtip]

$AIMD announced that it has obtained exclusive licenses for a total of 10 invention patents and patent applications from Taiwan Carbon Nano Technology ("TCNT"), the Company's affiliate and product co-developer.

https://finance.yahoo.com/news/ainos-secures-exclusive-multi-regions-201500321.html

[QuicKtip]

$CBDW 1606 Corp. Reports Great Success on IR Chat Sales Push and Shows Increased Revenue Last Quarter https://finance.yahoo.com/news/1606-corp-reports-great-success-120000601.html

[QuicKtip]

$CBDL HUGE NEWS - Vienna Vikings Football Team Signs Partnership Agreement With the CBD Vault https://finance.yahoo.com/news/vienna-vikings-football-team-signs-120000914.html

[QuicKtip]

$CBDW 1606 Corp is expanding AI innovations beyond investor relations into the solar, automotive, and finance industries. https://www.linkedin.com/posts/greg-lambrecht_ai-investorrelations-chatbot-activity-7224730617706397696-_xZ0?utm_source=share&utm_medium=member_desktop

[PinkPennies]

ASII .002 coming soon

[QuicKtip]

$ASII has secured a binding agreement with its lenders to exchange 100% of its currently outstanding convertible debt for a new series of preferred stock. https://finance.yahoo.com/news/accredited-solutions-reaches-agreement-convertible-120000876.html

[QuicKtip]

$CBDW 1606 Corp is expanding AI innovations beyond investor relations into the solar, automotive, and finance industries. https://www.linkedin.com/posts/greg-lambrecht_ai-investorrelations-chatbot-activity-7224730617706397696-_xZ0?utm_source=share&utm_medium=member_desktop